| 1 | Examining the Effectiveness of a Digital Media Campaign at Reducing the Duration of Untreated Psychosis in New York State: Results From a Stepped-wedge Randomized Controlled Trial | 4.3 | 2 | Citations (PDF) |
| 2 | Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis | 4.3 | 55 | Citations (PDF) |
| 3 | Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database | 2.9 | 7 | Citations (PDF) |
| 4 | Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis | 4.2 | 33 | Citations (PDF) |
| 5 | Relapse prevention through health technology program reduces hospitalization in schizophrenia | 4.2 | 12 | Citations (PDF) |
| 6 | The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia | 2.7 | 30 | Citations (PDF) |
| 7 | Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic | 2.7 | 3 | Citations (PDF) |
| 8 | Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options | 6.5 | 9 | Citations (PDF) |
| 9 | Changes in telepsychiatry regulations during the COVID-19 pandemic: 17 countries and regions' approaches to an evolving healthcare landscape | 4.2 | 107 | Citations (PDF) |
| 10 | Development of a computerized adaptive diagnostic screening tool for psychosis | 2.4 | 16 | Citations (PDF) |
| 11 | Striatal functional connectivity in psychosis relapse: A hypothesis generating study | 2.4 | 14 | Citations (PDF) |
| 12 | Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data | 4.3 | 39 | Citations (PDF) |
| 13 | Prevalence of impaired kidney function in patients with long‐term lithium treatment: A systematic review and meta‐analysis | 2.5 | 57 | Citations (PDF) |
| 14 | Acoustic and Facial Features From Clinical Interviews for Machine Learning–Based Psychiatric Diagnosis: Algorithm Development | 5.0 | 29 | Citations (PDF) |
| 15 | Digital and Mobile Health Technology in Collaborative Behavioral Health Care: Scoping Review | 5.0 | 26 | Citations (PDF) |
| 16 | Psychotropic Medication Use Is Associated With Greater 1-Year Incidence of Dementia After COVID-19 Hospitalization | 2.6 | 9 | Citations (PDF) |
| 17 | Post-acute college student satisfaction with telepsychiatry during the COVID-19 pandemic | 3.0 | 12 | Citations (PDF) |
| 18 | An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels | 2.9 | 204 | Citations (PDF) |
| 19 | Digital Strategies to Accelerate Help-Seeking in Youth With Psychiatric Concerns in New York State | 2.6 | 5 | Citations (PDF) |
| 20 | Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases | 1.1 | 28 | Citations (PDF) |
| 21 | The pharmacological treatment of schizophrenia: How far have we come? | 0.5 | 5 | Citations (PDF) |
| 22 | Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit | 5.2 | 3 | Citations (PDF) |
| 23 | Digital Technology in Psychiatry: Survey Study of Clinicians | 2.0 | 18 | Citations (PDF) |
| 24 | A Digital Intervention Using Daily Financial Incentives to Increase Medication Adherence in Severe Mental Illness: Single-Arm Longitudinal Pilot Study | 5.0 | 10 | Citations (PDF) |
| 25 | Cross-Platform Detection of Psychiatric Hospitalization via Social Media Data: Comparison Study | 5.0 | 8 | Citations (PDF) |
| 26 | Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit | 2.4 | 38 | Citations (PDF) |
| 27 | Development and Validation of a Computerized Adaptive Assessment Tool for Discrimination and Measurement of Psychotic Symptoms | 4.3 | 23 | Citations (PDF) |
| 28 | Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology | 4.9 | 11 | Citations (PDF) |
| 29 | Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia | 2.3 | 12 | Citations (PDF) |
| 30 | Antipsychotic Medications: Enhancing Use to Improve Outcomes | 4.3 | 3 | Citations (PDF) |
| 31 | A Social Media Study on Mental Health Status Transitions Surrounding Psychiatric Hospitalizations | 1.8 | 12 | Citations (PDF) |
| 32 | Authors’ Reply to Suhas et al.: Comment on: “Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation” | 3.6 | 0 | Citations (PDF) |
| 33 | Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations | 2.7 | 24 | Citations (PDF) |
| 34 | Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review | 5.2 | 28 | Citations (PDF) |
| 35 | Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies | 18.8 | 283 | Citations (PDF) |
| 36 | Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials | 1.3 | 30 | Citations (PDF) |
| 37 | Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort | 4.3 | 38 | Citations (PDF) |
| 38 | mHealth-Assisted Detection of Precursors to Relapse in Schizophrenia | 2.6 | 13 | Citations (PDF) |
| 39 | Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study | 4.3 | 73 | Citations (PDF) |
| 40 | Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile | 2.7 | 8 | Citations (PDF) |
| 41 | A systematic review and pooled, patient‐level analysis of predictors of mortality in neuroleptic malignant syndrome | 4.4 | 47 | Citations (PDF) |
| 42 | Utilizing Instagram Data to Identify Usage Patterns Associated With Schizophrenia Spectrum Disorders | 2.6 | 17 | Citations (PDF) |
| 43 | Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance | 4.3 | 16 | Citations (PDF) |
| 44 | Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis | 4.3 | 20 | Citations (PDF) |
| 45 | Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia | 6.5 | 61 | Citations (PDF) |
| 46 | Internet Search Activity of Young People With Mood Disorders Who Are Hospitalized for Suicidal Thoughts and Behaviors: Qualitative Study of Google Search Activity | 5.0 | 16 | Citations (PDF) |
| 47 | How to Make an Effective Offer of Clozapine | 2.8 | 4 | Citations (PDF) |
| 48 | Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review | 2.6 | 29 | Citations (PDF) |
| 49 | Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study | 4.2 | 39 | Citations (PDF) |
| 50 | Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study | 2.4 | 41 | Citations (PDF) |
| 51 | Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial | 2.4 | 9 | Citations (PDF) |
| 52 | Google search activity in early psychosis: A qualitative analysis of internet search query content in first episode psychosis | 2.1 | 13 | Citations (PDF) |
| 53 | The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research | 1.0 | 309 | Citations (PDF) |
| 54 | Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia | 2.4 | 32 | Citations (PDF) |
| 55 | Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics | 2.3 | 11 | Citations (PDF) |
| 56 | Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis | 18.8 | 96 | Citations (PDF) |
| 57 | Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia | 13.2 | 168 | Citations (PDF) |
| 58 | Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview | 1.5 | 83 | Citations (PDF) |
| 59 | Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool | 2.6 | 6 | Citations (PDF) |
| 60 | T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS | 4.3 | 2 | Citations (PDF) |
| 61 | The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services | 3.3 | 11 | Citations (PDF) |
| 62 | Identifying signals associated with psychiatric illness utilizing language and images posted to Facebook | 1.0 | 36 | Citations (PDF) |
| 63 | Consensus statement on the use of clozapine during the COVID-19 pandemic | 2.1 | 124 | Citations (PDF) |
| 64 | Clozapine and COVID-19: The authors respond | 2.1 | 2 | Citations (PDF) |
| 65 | There is a non-evidence-based app for that: A systematic review and mixed methods analysis of depression- and anxiety-related apps that incorporate unrecognized techniques | 4.8 | 46 | Citations (PDF) |
| 66 | Prolactin changes during electroconvulsive therapy: A systematic review and meta-analysis | 3.0 | 2 | Citations (PDF) |
| 67 | 185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials | 0.6 | 3 | Citations (PDF) |
| 68 | Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review | 2.7 | 35 | Citations (PDF) |
| 69 | Using therapeutic drug monitoring to personalize clozapine dosing in Asians | 2.6 | 42 | Citations (PDF) |
| 70 | Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia | 10.4 | 62 | Citations (PDF) |
| 71 | Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation | 3.6 | 42 | Citations (PDF) |
| 72 | Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies | 1.1 | 20 | Citations (PDF) |
| 73 | The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research | 1.1 | 15 | Citations (PDF) |
| 74 | Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study | 5.0 | 25 | Citations (PDF) |
| 75 | Predicting Early Warning Signs of Psychotic Relapse From Passive Sensing Data: An Approach Using Encoder-Decoder Neural Networks | 4.9 | 97 | Citations (PDF) |
| 76 | Patient Attitudes Toward Telepsychiatry During the COVID-19 Pandemic: A Nationwide, Multisite Survey | 5.0 | 94 | Citations (PDF) |
| 77 | Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice | 2.8 | 128 | Citations (PDF) |
| 78 | Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics | 2.8 | 19 | Citations (PDF) |
| 79 | Identifying emerging mental illness utilizing search engine activity: A feasibility study | 2.4 | 9 | Citations (PDF) |
| 80 | Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study | 2.4 | 41 | Citations (PDF) |
| 81 | Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics | 13.2 | 292 | Citations (PDF) |
| 82 | A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients | 2.7 | 100 | Citations (PDF) |
| 83 | Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference | 4.6 | 26 | Citations (PDF) |
| 84 | Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders | 13.2 | 67 | Citations (PDF) |
| 85 | Capturing behavioral indicators of persecutory ideation using mobile technology | 3.0 | 36 | Citations (PDF) |
| 86 | Predictors of Hospitalization of Individuals With First-Episode Psychosis: Data From a 2-Year Follow-Up of the RAISE-ETP | 2.3 | 41 | Citations (PDF) |
| 87 | Longitudinal associations of family burden and patient quality of life in the context of first-episode schizophrenia in the RAISE-ETP study | 3.3 | 17 | Citations (PDF) |
| 88 | Online help-seeking prior to diagnosis: Can web-based resources reduce the duration of untreated mood disorders in young people? | 4.8 | 30 | Citations (PDF) |
| 89 | Relationships between smartphone social behavior and relapse in schizophrenia: A preliminary report | 2.4 | 94 | Citations (PDF) |
| 90 | Structural similarity networks predict clinical outcome in early-phase psychosis | 5.5 | 49 | Citations (PDF) |
| 91 | Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia | 2.8 | 254 | Citations (PDF) |
| 92 | Clinically Significant Drug–Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder | 6.5 | 25 | Citations (PDF) |
| 93 | Is there a trial bias impacting user engagement with unguided e-mental health interventions? A systematic comparison of published reports and real-world usage of the same programs | 2.1 | 98 | Citations (PDF) |
| 94 | Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital | 2.4 | 33 | Citations (PDF) |
| 95 | Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis | 10.4 | 157 | Citations (PDF) |
| 96 | Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis | 4.9 | 854 | Citations (PDF) |
| 97 | Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics) | 2.8 | 52 | Citations (PDF) |
| 98 | Clinical risk factors for the development of tardive dyskinesia | 2.4 | 134 | Citations (PDF) |
| 99 | Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting | 2.3 | 18 | Citations (PDF) |
| 100 | Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis | 13.2 | 727 | Citations (PDF) |
| 101 | Factor structure of therapist fidelity to individual resiliency training in the Recovery After an Initial Schizophrenia Episode Early Treatment Program | 2.1 | 5 | Citations (PDF) |
| 102 | Demographic and clinical correlates of substance use disorders in first episode psychosis | 2.4 | 92 | Citations (PDF) |
| 103 | Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies | 4.3 | 168 | Citations (PDF) |
| 104 | Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? | 2.4 | 25 | Citations (PDF) |
| 105 | Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study | 2.4 | 34 | Citations (PDF) |
| 106 | Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia | 4.3 | 38 | Citations (PDF) |
| 107 | Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention | 10.4 | 60 | Citations (PDF) |
| 108 | Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis | 2.4 | 7 | Citations (PDF) |
| 109 | A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers | 2.4 | 47 | Citations (PDF) |
| 110 | Predictors of aggression in 3.322 patients with affective disorders and schizophrenia spectrum disorders evaluated in an emergency department setting | 2.4 | 16 | Citations (PDF) |
| 111 | Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials | 4.5 | 80 | Citations (PDF) |
| 112 | What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia? | 10.7 | 262 | Citations (PDF) |
| 113 | Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1 | 2.7 | 40 | Citations (PDF) |
| 114 | Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2 | 2.7 | 35 | Citations (PDF) |
| 115 | Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel Dataset | 4.9 | 129 | Citations (PDF) |
| 116 | Digital Peer-Support Platform (7Cups) as an Adjunct Treatment for Women With Postpartum Depression: Feasibility, Acceptability, and Preliminary Efficacy Study | 4.9 | 90 | Citations (PDF) |
| 117 | Revisiting the Abnormal Involuntary Movement Scale | 2.8 | 47 | Citations (PDF) |
| 118 | Role of social media and the <scp>I</scp>nternet in pathways to care for adolescents and young adults with psychotic disorders and non‐psychotic mood disorders | 2.1 | 137 | Citations (PDF) |
| 119 | Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis | 10.4 | 33 | Citations (PDF) |
| 120 | Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia | 13.2 | 205 | Citations (PDF) |
| 121 | CrossCheck: Integrating self-report, behavioral sensing, and smartphone use to identify digital indicators of psychotic relapse. | 1.0 | 168 | Citations (PDF) |
| 122 | Accuracy of Clinician Assessments of Medication Status in the Emergency Setting | 1.8 | 34 | Citations (PDF) |
| 123 | Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia | 5.5 | 63 | Citations (PDF) |
| 124 | Psychological well-being and mental health recovery in the NIMH RAISE early treatment program | 2.4 | 40 | Citations (PDF) |
| 125 | Improving outcomes of first‐episode psychosis: an overview | 10.7 | 504 | Citations (PDF) |
| 126 | Using Digital Media Advertising in Early Psychosis Intervention | 2.3 | 44 | Citations (PDF) |
| 127 | Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income | 2.4 | 89 | Citations (PDF) |
| 128 | Linguistic Markers Indicating Therapeutic Outcomes of Social Media Disclosures of Schizophrenia | 1.8 | 81 | Citations (PDF) |
| 129 | Enlight: A Comprehensive Quality and Therapeutic Potential Evaluation Tool for Mobile and Web-Based eHealth Interventions | 4.9 | 208 | Citations (PDF) |
| 130 | A Collaborative Approach to Identifying Social Media Markers of Schizophrenia by Employing Machine Learning and Clinical Appraisals | 4.9 | 156 | Citations (PDF) |
| 131 | Analyzing mHealth Engagement: Joint Models for Intensively Collected User Engagement Data | 4.9 | 64 | Citations (PDF) |
| 132 | Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and Be Most Promising for Predictive Algorithms for Conversion to Psychosis | 2.8 | 79 | Citations (PDF) |
| 133 | Dr Correll and Colleagues Reply | 2.8 | 1 | Citations (PDF) |
| 134 | Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine | 2.8 | 9 | Citations (PDF) |
| 135 | Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use | 2.8 | 241 | Citations (PDF) |
| 136 | Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors | 2.8 | 61 | Citations (PDF) |
| 137 | Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment | 2.8 | 77 | Citations (PDF) |
| 138 | Assessing Patients for Tardive Dyskinesia | 2.8 | 3 | Citations (PDF) |
| 139 | Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis | 2.8 | 34 | Citations (PDF) |
| 140 | Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials | 1.7 | 132 | Citations (PDF) |
| 141 | Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis | 4.3 | 167 | Citations (PDF) |
| 142 | Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics | 2.4 | 123 | Citations (PDF) |
| 143 | Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth | 1.7 | 25 | Citations (PDF) |
| 144 | Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis | 3.4 | 30 | Citations (PDF) |
| 145 | Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program | 10.4 | 790 | Citations (PDF) |
| 146 | Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment | 10.4 | 207 | Citations (PDF) |
| 147 | mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge | 5.0 | 138 | Citations (PDF) |
| 148 | The Use of Long-Acting Injectable Antipsychotics in Schizophrenia | 2.8 | 336 | Citations (PDF) |
| 149 | Schizophrenia | 50.7 | 1,028 | Citations (PDF) |
| 150 | Patterns and predictors of medication discrepancies in primary care | 1.8 | 35 | Citations (PDF) |
| 151 | Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review | 10.4 | 178 | Citations (PDF) |
| 152 | Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics | 2.5 | 37 | Citations (PDF) |
| 153 | Objective identification and analysis of physiological and behavioral signs of schizophrenia | 2.8 | 29 | Citations (PDF) |
| 154 | Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia | 13.2 | 333 | Citations (PDF) |
| 155 | Ambiguous findings concerning potential advantages of depot antipsychotics | 4.4 | 50 | Citations (PDF) |
| 156 | The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components | 2.3 | 218 | Citations (PDF) |
| 157 | Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study | 1.7 | 8 | Citations (PDF) |
| 158 | Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders | 4.3 | 52 | Citations (PDF) |
| 159 | Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset Schizophrenia | 4.3 | 11 | Citations (PDF) |
| 160 | A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes | 4.3 | 110 | Citations (PDF) |
| 161 | Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002–2012) | 2.4 | 23 | Citations (PDF) |
| 162 | Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study | 4.3 | 68 | Citations (PDF) |
| 163 | Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study | 10.4 | 328 | Citations (PDF) |
| 164 | Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study | 10.4 | 87 | Citations (PDF) |
| 165 | The Role of NMDA Receptors in Schizophrenia | 2.8 | 4 | Citations (PDF) |
| 166 | The RAISE Early Treatment Program for First-Episode Psychosis | 2.8 | 149 | Citations (PDF) |
| 167 | Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders | 13.2 | 358 | Citations (PDF) |
| 168 | Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies | 2.4 | 28 | Citations (PDF) |
| 169 | Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials | 4.3 | 355 | Citations (PDF) |
| 170 | Antidepressants for cognitive impairment in schizophrenia — A systematic review and meta-analysis | 2.4 | 57 | Citations (PDF) |
| 171 | BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis | 2.4 | 21 | Citations (PDF) |
| 172 | Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients | 2.4 | 84 | Citations (PDF) |
| 173 | Rapid clozapine titration in treatment-refractory bipolar disorder | 4.8 | 50 | Citations (PDF) |
| 174 | Attitudinal Barriers to Prescribing LAI Antipsychotics in the Outpatient Setting | 2.8 | 10 | Citations (PDF) |
| 175 | Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study | 2.4 | 116 | Citations (PDF) |
| 176 | Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies | 10.7 | 445 | Citations (PDF) |
| 177 | Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia | 2.8 | 405 | Citations (PDF) |
| 178 | Improving Patient Outcomes in Schizophrenia | 2.8 | 34 | Citations (PDF) |
| 179 | Termination of Clozapine Treatment Due to Medical Reasons | 2.8 | 223 | Citations (PDF) |
| 180 | Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients | 5.5 | 51 | Citations (PDF) |
| 181 | Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia | 1.8 | 114 | Citations (PDF) |
| 182 | Past and Present Progress in the Pharmacologic Treatment of Schizophrenia | 2.8 | 205 | Citations (PDF) |
| 183 | Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia | 10.4 | 192 | Citations (PDF) |
| 184 | Pharmacologic treatment of schizophrenia | 5.6 | 103 | Citations (PDF) |
| 185 | Clinical guideline recommendations for antipsychotic long-acting injections | 1.9 | 128 | Citations (PDF) |
| 186 | Cognitive deficits in schizophrenia: short‐term and long‐term | 10.7 | 9 | Citations (PDF) |
| 187 | Clinical Insights Into Pharmacogenetics and Schizophrenia, Part 2 | 2.8 | 1 | Citations (PDF) |
| 188 | Utilization of Long-Acting Antipsychotic Medication in Patient Care | 0.6 | 30 | Citations (PDF) |
| 189 | Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) | 2.8 | 34 | Citations (PDF) |
| 190 | Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies | 10.4 | 682 | Citations (PDF) |
| 191 | Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic | 10.4 | 481 | Citations (PDF) |
| 192 | Treatment Models and Designs for Intervention Research During the Psychotic Prodrome | 4.3 | 17 | Citations (PDF) |
| 193 | Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder | 2.8 | 534 | Citations (PDF) |
| 194 | Side effects of antipsychotic drugs | 2.8 | 19 | Citations (PDF) |
| 195 | Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors | 10.4 | 227 | Citations (PDF) |
| 196 | Methylphenidate Response, Psychopathology and Tardive Dyskinesia as Predictors of Relapse in Schizophrenia | 5.5 | 63 | Citations (PDF) |
| 197 | Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview | 1.9 | 152 | Citations (PDF) |
| 198 | Obstacles to Clinical Research and New Drug Development in Schizophrenia | 4.3 | 9 | Citations (PDF) |
| 199 | Research Diagnoses for Tardive Dyskinesia | 13.6 | 792 | Citations (PDF) |
| 200 | Awareness of illness moderates self-assessment of psychotic symptoms | 3.4 | 3 | Citations (PDF) |
